Clinical Trials
12 trialsNCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07598955 2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2 Recruiting
NCT02133196 2026-05-13
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07510815 2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05681780 2026-03-31
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT06885697 2026-02-17
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07246304 2025-11-24
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT06630611 2025-01-28
PragmaTIL
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT06538012 2024-10-15
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT04282044 2024-02-08
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
Phase 1 Recruiting